sava stock
AUSTIN, Texas, Nov. 24, 2024 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (NASDAQ: SAVA), a clinical-stage biotechnology company focused on developing treatments for Alzheimer’s disease, has announced it will host a conference call and webcast on Monday, November 25th, at 8:00 a.m. Eastern Time. The webcast will be available for replay on the Cassava Sciences website under the Company Presentations page for 90 days following the event.
About Cassava Sciences, Inc.
Cassava Sciences is dedicated to the detection and treatment of neurodegenerative diseases, with a primary focus on Alzheimer’s disease. Headquartered in Austin, Texas, the company is advancing its investigational oral drug, Simufilam, which is currently undergoing two Phase 3 clinical trials for the treatment of Alzheimer’s disease.
Simufilam is an experimental small molecule that targets the filamin A protein and has shown promise in preclinical and clinical studies. Cassava Sciences holds exclusive, worldwide rights to Simufilam and its associated technologies, with no royalty obligations to third parties.
For more information on the company’s pipeline and ongoing clinical trials, visit the Cassava Sciences website.